INmune Bio Inc. - Common stock (INMB)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- P/B of 1.94 — trading above book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -234.8%
- Revenue growing at 257% annually
INmune Bio Inc. - Common stock (INMB) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $38 million . Key value metrics: P/B ratio 1.94, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
INmune Bio Inc. - Common stock — Fundamental Analysis Summary
On financial health, INMB shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -234.8% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.76.
StockPik's composite Value Score for INMB is 35/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
INMB shows revenue growing at 257% year-over-year, with earnings declining at 9%.